AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in pharmaceutical business focusing on the research, development, manufacturing and commercialization of prescription medicines. Co. is focused on its therapy areas: Oncology, which provides Tagrisso (osimertinib) for lung cancer; BioPharmaceuticals, which provides Farxiga/ Forxiga (dapagliflozin) for Type-2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease; and Rare Disease, which provides Soliris (eculizumab) for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis and neuromyelitis optica spectrum disorder. When considering the AstraZeneca Plc stock dividend history, we have taken known splits into account, such that the AZN dividend history is presented on a split-adjusted ("apples to apples") basis. AstraZeneca Plc dividend history is presented both in graphical/chart form, and as a AZN dividend history data table along the right-hand column.
|
AZN Stock Dividend HistoryThe AZN dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable AZN historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the AZN dividend history record. Also see the AZN stock dividend history data table along the right-hand column below. |
|
AZN Next Dividend Date » (Projection based upon history) AZN Dividend Growth Rate » Quotes delayed 20 minutes |
Strong Buy (3.59 out of 4) 65th percentile
(ranked higher than approx. 65% of all stocks covered)
Analysts' Target Price: AZN Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection: AZN Next Dividend Date Chart: AZN Chart - 5Yr Dividend Yield |